哌拉西林他唑巴坦联合阿米卡星对支气管扩张感染患者炎症水平及肺功能的影响  

Effect of Piperacillin-Tazobactam Combined with Amikacin on Inflammation Level and Lung Function in Patients with Bronchiectasis Infection

作　　者：连广学 郭娟 LIAN Guang-xue;GUO Juan(Department of Respiratory and Critical Care Medicine,Wuyang County People's Hospital,Luohe 462400,China)

机构地区：[1]舞阳县人民医院呼吸与危重症医学科,漯河462400

出　　处：《四川解剖学杂志》2024年第6期20-22,共3页Sichuan Journal of Anatomy

摘　　要：目的:探讨哌拉西林他唑巴坦联合阿米卡星在支气管扩张感染患者中的应用效果.方法:选取2022年1月至2024年1月本院收治的98例支气管扩张合并感染患者作为研究对象.按照治疗方式,将其分为研究组(n=49,采用哌拉西林他唑巴坦联合阿米卡星治疗)和对照组(n=49,采用哌拉西林他唑巴坦治疗).比较两组患者临床疗效、炎症指标、肺功能指标及不良反应发生情况.结果:治疗后,研究组患者治疗总有效率高于对照组,差异有统计学意义(P<0.05);研究组患者白细胞计数(WBC)、C反应蛋白(CRP)、红细胞沉降率(ESR)水平均低于对照组,最大呼气流速(PEF)、第1秒用力呼气容积(FEV1)、FEV_(1)/用力肺活量(FVC)水平均高于对照组,差异均有统计学意义(P<0.05);两组患者不良反应总发生率比较,差异无统计学意义(P>0.05).结论:支气管扩张感染患者采用哌拉西林他唑巴坦联合阿米卡星治疗,利于减轻机体炎症反应,促进肺功能恢复,且用药安全性较高,值得临床推广.Objective:To explore the effects of piperacillin-tazobactam combined with amikacin in patients with bronchiectasis infection.Methods:A total of 98 patients with bronchiectasis combined with infection admitted to our hospital from January 2022 to January 2024 were selected as research subjects.They were divided into study group(n=49,treated with piperacillin-tazobactam combined with amikacin)and control group(n=49,treated with piperacillin tazobactam),according to treatment protocol.The clinical efficacy,inflammatory indicators,lung function indicators and adverse reactions of the two groups were compared.Results:After treatment,the total effective rate of study group was higher than that of control group,and the difference was statistically significant(P<0.05).The levels of white blood cell count(WBC),C-reactive protein(CRP)and erythrocyte sedimentation rate(ESR)in study group were lower than those in control group,the levels of peak expiratory flow(PEF),forced expiratory volume in 1 second(FEV_(1))and FEV_(1)/forced vital capacity(FVC)in study group were higher than those in control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Piperacillin-tazobactam combined with amikacin in the treatment of patients with bronchiectasis infection can reduce the inflammatory response of the body,and promote the recovery of lung function,which is safe and worthy of clinical promotion.

关 键 词：支气管扩张 感染 阿米卡星 哌拉西林他唑巴坦 炎症因子 肺功能 

分 类 号：R47[医药卫生—护理学]